Patent for treating inflammatory diseases via tuft cell surface receptors

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 31st, 2026

Detected March 31st, 2026

Summary

The USPTO granted Broad Institute Patent US12590288B2 covering methods of treating inflammatory diseases (including IBD and asthma) by administering agents that bind tuft cell surface receptors to induce ILC2 inflammatory responses. The patent names six inventors including Jayaraj Rajagopal and Aviv Regev, and includes 20 claims. This grant provides Broad Institute exclusive rights to the disclosed therapeutic methods for a 20-year period from the 2018 filing date.

View original document View source feed page

What changed

The USPTO issued Patent US12590288B2 to The Broad Institute, Inc. on March 31, 2026, covering methods of treating inflammatory diseases by administering agents that bind surface receptors on tuft cells to induce Type 2 innate lymphoid cell (ILC2) inflammatory responses. The patent includes 20 claims and covers treatments for conditions including inflammatory bowel disease (IBD) and asthma. The technology is based on research identifying intestinal epithelial cell populations and their role in immune responses.

Pharmaceutical companies and researchers developing treatments targeting tuft cells or ILC2 pathways should review this patent to assess freedom-to-operate considerations. The patent expires April 12, 2038, based on the original filing date. Entities conducting related research or development in this therapeutic area should consult with IP counsel regarding potential licensing needs or design-around options.

Source document (simplified)

← USPTO Patent Grants

Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response

Grant US12590288B2 Kind: B2 Mar 31, 2026

Assignee

The Broad Institute, Inc.

Inventors

Jayaraj Rajagopal, Aviv Regev, Moshe Biton, Adam Haber, Daniel Montoro, Ramnik Xavier

Abstract

An atlas of intestinal epithelial cells, intestinal epithelial stem cells and intestinal immune cells identifies new cell populations, markers, networks, and responses to stimuli. Intestinal epithelial cell sub-types are also found in the trachea. Accordingly, disclosed are methods of modulating epithelial cell differentiation, maintenance and/or function, related methods for the treatment of disease, including IBD and asthma. Also disclosed are methods and kits for identifying cell types, their differentiation, homeostasis and activation.